Timothy Coughlin - 03 Jun 2025 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Role
Director
Signature
/s/ Lisa Kallebo, as Attorney-in-fact for Timothy Coughlin
Issuer symbol
ADCT
Transactions as of
03 Jun 2025
Net transactions value
$0
Form type
4
Filing time
05 Jun 2025, 17:13:04 UTC
Previous filing
16 May 2025
Next filing
04 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
COUGHLIN TIMOTHY Director 430 MOUNTAIN AVENUE, SUITE 404, NEW PROVIDENCE /s/ Lisa Kallebo, as Attorney-in-fact for Timothy Coughlin 05 Jun 2025 0001376043

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADCT Common Shares Award $0 +40,000 $0.000000 40,000 03 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADCT Stock Options (Right to Buy) Award $0 +80,000 $0.000000 80,000 03 Jun 2025 Common Shares 80,000 $3.59 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents a one-time initial stock option award made under the Issuer's 2019 Equity Incentive Plan. The options vest over four years from June 3, 2025, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.